The significance of different formulations of aerosolized colistin

Mubareka S, Rubinestein E: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9: 29-30. 10.1186/cc3036 Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9: R53-R59. 10.1186/cc3020 Falagas ME, Kasiakou SK: Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005, in press. Falagas ME, Choulis N, Michalopoulos A: Polymyxins. In Antimicrobial Therapy. 2nd edition. Edited by: Yu V. New York: Apple Trees Productions, LCC; 2005:in press. Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM: Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cystic Fibrosis 2004, 3: 23-28. 10.1016/j.jcf.2003.12.005 Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J: Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003, 52: 987-992. 10.1093/jac/dkg468 Berlana D, Llop JM, Badia MB, Jodar R: Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am J Health-Syst Pharm 2005, 62: 39-47.